News and Press Releases
PlaqueTec closes $8m equity financing
The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support ongoing BIOPATTERN trial and build BIOCARTA database to transform...
Category: Biotechnology, Other, Pharmaceutical
Posted: April 30, 2024
Asahi Kasei Bioprocess to Unveil THESYS ACS ERGO Synthesis Column at TIDES USA – offering reduced changeover time while maintaining safety and product quality
30 April 2024 -- Düsseldorf, Germany; Tokyo, Japan; and New York, US -- Generating cutting-edge therapeutics requires precision, safety and efficiency from manufacturing equipment. The next generation of oligo manufacturing,...
Category: BioManufacturing, Manufacturing and Packing
Posted: April 30, 2024
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
Stable lentiviral (LV) cell line development service achieves unconcentrated titres >1E9 TU/mL for therapeutic transgenes Fully stable cell lines have all viral genes and transgene stably integrated, enabling biomanufacturing scalability...
Category: Biotechnology, Pharmaceutical
Posted: April 29, 2024
Johnson & Johnson receives positive CHMP opinion for RYBREVANT▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC The recommendation is...
Category: Clinical Trials, Pharmaceutical
Posted: April 29, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Owlstone Medical Secures $6.5m to Support Development of Breath-based Diagnostics for Infectious Disease
$5m equity investment and initial $1.5m grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing world Funding...
Category: Biotechnology, Other
Posted: April 25, 2024
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
SnapSlide introduces first child-resistant closure with single-handed operation for Rx amber vials
Also available for OTC applications, patented solution brings life-changing potential for over 60 million Americans with physical limitations, while also reducing plastic usage. 24 April 2024 – Scranton, PA, US...
Category: Logistics, Manufacturing and Packing
Posted: April 24, 2024
Tower Cold Chain unveils an industry-first container design
23 April 2024 – Tower Cold Chain, a leader in passive temperature-controlled containers, has unveiled the KTEvolution 12, setting a new standard in small parcel solutions for pharmaceutical products, thanks...
Category: Logistics, Manufacturing and Packing
Posted: April 24, 2024
Unit A, Total Park, Station Road, Theale, Reading, Berkshire RG7 4PN, UK
CN Bio raises $21m in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10m and $5.5m, respectively Investment will expand product development and scaling of the organisation to meet increased demand for...
Category: Biotechnology, Drug Discovery, Other
Posted: April 23, 2024
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programmes 23 April 2024 -- Oslo, Norway -- Calluna Pharma, a clinical stage company pioneering a...
Category: Other, Pharmaceutical
Posted: April 23, 2024
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator
23 April 2024 -- Brussels, Belgium -- Myeloma Patients Europe (MPE) has launched today the English version of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search...
Category: Clinical Trials, Pharmaceutical
Posted: April 23, 2024
CARVYKTI▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the EC for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from...
Category: Biotechnology, Clinical Trials
Posted: April 22, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Over a thousand people with multiple myeloma may be eligible for treatment with Nexpovio▼ (selinexor) following NICE recommendation addressing ‘significant unmet need’ for this incurable blood cancer
NEXPOVIO has been recommended for use in the NHS, offering the opportunity to improve patient outcomes in this challenging and complex cancer NEXPOVIO has the potential to address significant treatment...
Category: Biotechnology, Pharmaceutical
Posted: April 22, 2024
How the Birmingham Drug Discovery Hub created an investment-ready ‘drug library’
18 April 2024 -- Birmingham, UK -- A novel approach to drug discovery is enabling University of Birmingham, UK, researchers to overcome the ‘valley of death’, where projects fail due...
Category: Drug Discovery
Posted: April 18, 2024
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolytics to advance lead candidate THEO-260...
Category: Biotechnology, Drug Discovery
Posted: April 17, 2024
The Sherard Building, Edmund Halley Road, Oxford Science Park, Oxford. OX4 4DQ
Sphere Fluidics appoints Edward Rayner as non-executive director
Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth 17 April 2024 – Cambridge, UK – Sphere Fluidics, a...
Category: Drug Discovery
Posted: April 17, 2024
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
